Moderna Stocks - price, description, and characteristics
A biotechnology business called Moderna, Inc. discovers, develops, and commercializes messenger RNA therapies and vaccines for the treatment of infectious illnesses, immuno-oncology, rare diseases, cardiovascular disorders, and autoimmune diseases in the United States, Europe, and other countries.
Vaccines developed by Moderna are divided into:
-
Respiratory (COVID-19, influenza, respiratory syncytial virus, endemic HCoV and hMPV+PIV3 vaccines)
-
Latent (cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus and varicella-zoster virus vaccines)
-
Public health vaccines (Zika and Nipah)
It has strategic partnerships with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici.
Moderna company was originally known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Cambridge, Massachusetts serves as the corporate headquarters for Moderna, Inc., which was established in 2010.
Stéphane Bancel has been the Chief Executive Officer of Moderna since October 2011 and a member of the board of directors since March 2011. Moderna's President and Director of Research & Development is Stephen Hoge. For over ten years, Dr. Hoge has overseen Moderna's scientific endeavors.